A UK study has shown that cancer patients are less safe after the first cod vaccine

A UK study has shown that cancer patients are less safe after the first cod vaccine

LONDON: Cancer patients will not get the same degree as the rest of the population after taking their first two doses of the Code-19 vaccine, a new UK study found on Thursday.
A team of experts from King’s College London and the Francis Kirk Institute said in a first-of-its-kind real-world study that for such patients, the response was less than 12 weeks between two vaccines.
The study’s senior authors, Dr Sheiba Irshad and Professor Adrian Hyde, believe that there should be an immediate review of the UK’s policy on diet breaks for all cancer patients, as well as many other immunocompromised patients. Also for high risk groups.
“Our data provide the first real-world evidence of immune efficacy after a single dose of an immunization vaccine,” said Dr Sheiba Irshad, a senior clinical lecturer at King’s College London’s School of Cancer and Pharmaceutical Sciences.
“We show that after the first dose, most solid and hematologic cancer patients remain immunocompromised for at least five weeks after the initial injection. Utility can be saved, “he said.
The world’s first reported trial data to test the level of immunity in cancer patients after the Pfizer / biotic vaccine showed that the anti-SARS co-2 virus, which causes covid 19 – Antibody responses After three weeks, the vaccine dose was only 39%, and in hematological cancers only 13%, while in cancer patients it was 97%.
The pre-print study, which is to be peer-reviewed, also shows that when the second dose of the vaccine was given three weeks after the first dose, there was a significant improvement in the immune response for stable cancer patients, including About 95% of antibodies were detected. SARS-CoV-2 virus in just two weeks.
In contrast, those who did not receive the vaccine increase in three weeks did not see any real improvement, with only 43% of solid cancer patients and 8% of blood cancer patients developing antibodies to the Pfizer vaccine. Percentage of healthy control in five weeks compared
Evidence of a vaccine response in cancer patients suggests that a 12-week interval between doses of Pfizer biotech vaccines may put many cancer patients at risk for serious covid 19.
Adrian Hyde, a professor at King’s College London and Francis Kirk Institute, said: “Cancer patients should be vaccinated immediately and they should be raised and their reactions, especially those of blood cancer patients, should be closely monitored.” People who meet family, friends and caregivers. You can trust your environment.
Dr Simon Vincent, director of research, support and influenza at Breast Cancer Now, called on the Joint Committee on Vaccination and Immunization (JCVI), which determines the UK’s vaccine rollout groups, to look into the evidence. Immediate review should be done and consideration should be given to their adoption to ensure its strategy. That cancer patients can receive both the first and second doses of the Pfizer / Biotech Quide-19 vaccine within a three-week time frame to reduce their risk of contracting and becoming seriously ill with the coronavirus.
“The most worrying thing is that this study shows that people with cancer, including breast cancer, get little protection from the virus when they receive only a single dose of the Pfizer Covid 19 vaccine, and then for the next three weeks. I do not promote my vaccine. , “They said.
But Cancer Research UK said the small study had not yet been reviewed by other scientists and that people undergoing cancer treatment should follow the advice of their doctors, while the government says antibody reactions. It was just part of the protection provided by the vaccine. ” .
Meanwhile, a UK study will continue to follow cancer patients for six months after vaccination.

STAY TUNED WITH US FOR MORE INTERESTING CONTENT ONLY ON DESINEW.XYZ

Leave a Reply

Your email address will not be published. Required fields are marked *